Development of a new therapy for refractory ovarian cancer via liposomal nanoparticle targeting control of EMT
Description: We produced liposomal cisplatin to treat ovarian cancer cells. In order to target CD24-positive cells, an anti-CD24 monoclonal antibody was modified to the above drug, because we have found that CD24 is involved in ovarian cancer metastasis through up-regulation of epithelial-mesenchymal transition (EMT). Treatment of our liposomal cisplatin with anti-CD24 andibody inhibited EMT. Furthermore, significantly prolonged survival was observed under treatment of the above liposomal cisplatin compared with that of cisplatin or liposomal cisplatin without anti-CD24 antibody. These results suggest the potential of targeting anticancer therapeutics for CD24-positive ovarian cancer cells to prevent disease progression.
Amount: ¥4,680,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2017-04-01
End date: 2020-03-31
Investigator: Masahide Ohmichi
Institution: Osaka Medical College
Funded outputs count: 2
Funder award ID: 17K11304
OpenAlex ID: G7038577631